Literature DB >> 28461599

Risk Factors for Nonadherence to Antihypertensive Treatment.

Pankaj Gupta1, Prashanth Patel1, Branislav Štrauch1, Florence Y Lai1, Artur Akbarov1, Věra Marešová1, Christobelle M J White1, Ondřej Petrák1, Gaurav S Gulsin1, Veena Patel1, Ján Rosa1, Richard Cole1, Tomáš Zelinka1, Robert Holaj1, Angela Kinnell1, Paul R Smith1, John R Thompson1, Iain Squire1, Jiří Widimský1, Nilesh J Samani1, Bryan Williams1, Maciej Tomaszewski2.   

Abstract

Nonadherence to antihypertensive treatment is a critical contributor to suboptimal blood pressure control. There are limited and heterogeneous data on the risk factors for nonadherence because few studies used objective-direct diagnostic methods. We used high-performance liquid chromatography-tandem mass spectrometry of urine and serum to detect nonadherence and explored its association with the main demographic- and therapy-related factors in 1348 patients with hypertension from 2 European countries. The rates of nonadherence to antihypertensive treatment were 41.6% and 31.5% in the UK and Czech populations, respectively. Nonadherence was inversely related to age and male sex. Each increase in the number of antihypertensive medications led to 85% and 77% increase in nonadherence (P<0.001) in the UK and Czech populations, respectively. The odds of nonadherence to diuretics were the highest among 5 classes of antihypertensive medications (P≤0.005 in both populations). The predictive model for nonadherence, including age, sex, diuretics, and the number of prescribed antihypertensives, showed area under the curves of 0.758 and 0.710 in the UK and Czech populations, respectively. The area under the curves for the UK model tested on the Czech data and for the Czech model tested on UK data were calculated at 0.708 and 0.756, respectively. We demonstrate that the number and class of prescribed antihypertensives are modifiable risk factors for biochemically confirmed nonadherence to blood pressure-lowering therapy. Further development of discriminatory models incorporating these parameters might prove clinically useful in assessment of nonadherence in countries where biochemical analysis is unavailable.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  adherence; blood pressure; diuretics; hypertension; polypharmacy

Mesh:

Substances:

Year:  2017        PMID: 28461599     DOI: 10.1161/HYPERTENSIONAHA.116.08729

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  44 in total

Review 1.  Hypertension: history and development of established and novel treatments.

Authors:  Milan Wolf; Sebastian Ewen; Felix Mahfoud; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2018-06-27       Impact factor: 5.460

2.  Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency.

Authors:  Nilay Kumar; Shawn Simek; Neetika Garg; Muthiah Vaduganathan; Farah Kaiksow; James H Stein; Gregg C Fonarow; Ambarish Pandey; Deepak L Bhatt
Journal:  Hypertension       Date:  2019-01       Impact factor: 10.190

3.  Novel stratified medicines approach to manage uncontrolled hypertension due to multiple drug intolerances.

Authors:  Catherine Schuster Bruce; Gurvinder Rull; Antoniou Sotiris; Melvin D Lobo
Journal:  BMJ Case Rep       Date:  2018-12-13

4.  Clarification of the Correct Nomenclature of the Amino Metabolite of Clonazolam: 8-Aminoclonazolam.

Authors:  Peter D Maskell; Claire Parks; Jenny Button; Huiling Liu; Denise A McKeown
Journal:  J Anal Toxicol       Date:  2021-02-13       Impact factor: 3.367

Review 5.  Advancing the Science and Practice of Medication Adherence.

Authors:  Michael J Stirratt; Jeffrey R Curtis; Maria I Danila; Richard Hansen; Michael J Miller; C Ann Gakumo
Journal:  J Gen Intern Med       Date:  2018-02       Impact factor: 5.128

6.  Hypertension: Device therapy for uncontrolled hypertension: new approaches to an old problem.

Authors:  Peter J Blankestijn; Michiel L Bots
Journal:  Nat Rev Nephrol       Date:  2017-11-15       Impact factor: 28.314

7.  Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence.

Authors:  Mohammed Siddiqui; Eric K Judd; Tanja Dudenbostel; Bin Zhang; Pankaj Gupta; Maciej Tomaszewski; Prashanth Patel; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2019-07-22       Impact factor: 10.190

8.  Adherence to multiple medications in the TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) cohort: effect of additional medications on adherence to primary diabetes medication.

Authors:  Rachana Shah; Siripoom V McKay; Lorraine E Levitt Katz; Laure El Ghormli; Barbara J Anderson; Terri L Casey; Laurie Higgins; Roberto Izquierdo; Aimee D Wauters; Nancy Chang
Journal:  J Pediatr Endocrinol Metab       Date:  2020-02-25       Impact factor: 1.634

9.  Systolic Blood Pressure and Biochemical Assessment of Adherence: A Cross-Sectional Analysis in the Emergency Department.

Authors:  Candace D McNaughton; Nancy J Brown; Russell L Rothman; Dandan Liu; Edmond K Kabagambe; Phillip D Levy; Wesley H Self; Alan B Storrow; Sean P Collins; Christianne L Roumie
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

10.  Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.

Authors:  Valeria Avataneo; Amedeo De Nicolò; Franco Rabbia; Elisa Perlo; Jacopo Burrello; Elena Berra; Marco Pappaccogli; Jessica Cusato; Antonio D'Avolio; Giovanni Di Perri; Franco Veglio
Journal:  Br J Clin Pharmacol       Date:  2018-08-15       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.